Tolterodine L-Tartrate shortage — BE supply status & alternatives

Tolterodine L-Tartrate

—

In supply · Australia

Detrusitol Retard

In supply · 🇦🇺 Australia · short in🇧🇪 BE🌐 IS

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Tolterodine L-Tartrate
Brand names	Detrusitol Retard
Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 10 resolved events

◷

0–6 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🌐

IMA · 19h ago

Resolved

🇧🇪

FAMHP · 19d ago

Medium

Verified timeline regulator events

🌐 9 June 2026

Shortage resolved

🇧🇪 20 May 2026

medium reported

🌐 10 Apr 2026

medium reported

🌐 15 Jan 2026

Shortage resolved

🌐 9 Dec 2025

Shortage resolved

🌐 24 Nov 2025

Shortage resolved

Sources official regulators

🌐

IMA

verified 19h ago

verify ↗

🇧🇪

FAMHP

verified 19d ago

verify ↗

Mederti Drug Report

Generated 3 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.